BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26167688)

  • 1. Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy.
    Zhao Y; Liu L; Huang J; Shi S; Lv J; Liu G; Zhao M; Zhang H
    PLoS One; 2015; 10(7):e0132869. PubMed ID: 26167688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.
    Guo SM; Han M; Chen MX; Ning Y; Pei GC; Li YQ; Dai W; Ge SW; Deng YJ; Guo YY; Li XQ; Haller H; Xu G; Rong S
    PLoS One; 2015; 10(9):e0138718. PubMed ID: 26380984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
    Huang J; Liu G; Zhang YM; Cui Z; Wang F; Liu XJ; Chu R; Zhao MH
    BMC Med; 2014 May; 12():81. PubMed ID: 24884842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
    Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
    Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.
    Spinale JM; Mariani LH; Kapoor S; Zhang J; Weyant R; Song PX; Wong HN; Troost JP; Gadegbeku CA; Gipson DS; Kretzler M; Nihalani D; Holzman LB;
    Kidney Int; 2015 Mar; 87(3):564-74. PubMed ID: 25354239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.
    Sinha A; Bajpai J; Saini S; Bhatia D; Gupta A; Puraswani M; Dinda AK; Agarwal SK; Sopory S; Pandey RM; Hari P; Bagga A
    Kidney Int; 2014 Mar; 85(3):649-58. PubMed ID: 24429405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
    Alachkar N; Wei C; Arend LJ; Jackson AM; Racusen LC; Fornoni A; Burke G; Rabb H; Kakkad K; Reiser J; Estrella MM
    Transplantation; 2013 Oct; 96(7):649-56. PubMed ID: 23842190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy.
    Bellur SS; Lepeytre F; Vorobyeva O; Troyanov S; Cook HT; Roberts IS;
    Kidney Int; 2017 Jan; 91(1):235-243. PubMed ID: 27914703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.
    Jin J; Li YW; He Q
    Transplant Proc; 2015; 47(6):1760-5. PubMed ID: 26293047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.
    Meijers B; Maas RJ; Sprangers B; Claes K; Poesen R; Bammens B; Naesens M; Deegens JK; Dietrich R; Storr M; Wetzels JF; Evenepoel P; Kuypers D
    Kidney Int; 2014 Mar; 85(3):636-40. PubMed ID: 24402090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TWEAK/Fn14 system and crescent formation in IgA nephropathy.
    Sasaki Y; Shimizu Y; Suzuki Y; Horikoshi S; Tomino Y
    BMC Nephrol; 2015 Mar; 16():27. PubMed ID: 25885587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.
    Alfano M; Cinque P; Giusti G; Proietti S; Nebuloni M; Danese S; D'Alessio S; Genua M; Portale F; Lo Porto M; Singhal PC; Rastaldi MP; Saleem MA; Mavilio D; Mikulak J
    Sci Rep; 2015 Sep; 5():13647. PubMed ID: 26380915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].
    Segarra A; Jatem E; Quiles MT; Arbós MA; Ostos H; Valtierra N; Carnicer C; Salcedo MT
    Nefrologia; 2014; 34(1):53-61. PubMed ID: 24463863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
    Harel E; Shoji J; Abraham V; Miller L; Laszik ZG; King A; Dobi D; Szabo G; Hann B; Sarwal MM; Craik CS; Vincenti F
    Transplantation; 2020 Jan; 104(1):54-60. PubMed ID: 31449183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy.
    Asao R; Asanuma K; Kodama F; Akiba-Takagi M; Nagai-Hosoe Y; Seki T; Takeda Y; Ohsawa I; Mano S; Matsuoka K; Kurosawa H; Ogasawara S; Hirayama Y; Sekine S; Horikoshi S; Hara M; Tomino Y
    Clin J Am Soc Nephrol; 2012 Sep; 7(9):1385-93. PubMed ID: 22700887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoexpression of podocyte-associated proteins in acquired human glomerulopathies with nephrotic syndrome.
    Wagrowska-Danilewicz M; Stasikowska O; Danilewicz M
    Pol J Pathol; 2006; 57(1):17-21. PubMed ID: 16739878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translocation of dendrin to the podocyte nucleus in acute glomerular injury in patients with IgA nephropathy.
    Kodama F; Asanuma K; Takagi M; Hidaka T; Asanuma E; Fukuda H; Seki T; Takeda Y; Hosoe-Nagai Y; Asao R; Horikoshi S; Tomino Y
    Nephrol Dial Transplant; 2013 Jul; 28(7):1762-72. PubMed ID: 23143340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble Urokinase Receptor and Chronic Kidney Disease.
    Hayek SS; Sever S; Ko YA; Trachtman H; Awad M; Wadhwani S; Altintas MM; Wei C; Hotton AL; French AL; Sperling LS; Lerakis S; Quyyumi AA; Reiser J
    N Engl J Med; 2015 Nov; 373(20):1916-25. PubMed ID: 26539835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of renal clinicopathological changes in IgA nephropathy by urinary podocytes excretion and podocalyxin expression.
    Jiang WL; Peng YM; Liu YH; Liu H; Chen GC; Xu XQ; Zhu XJ; Liu FY
    Ren Fail; 2012; 34(7):821-6. PubMed ID: 22679920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies.
    El Karoui K; Hill GS; Karras A; Moulonguet L; Caudwell V; Loupy A; Bruneval P; Jacquot C; Nochy D
    Kidney Int; 2011 Mar; 79(6):643-654. PubMed ID: 21178978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.